503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
2026 Head-to-Head Fee & Dose-Escalation Teardown · DOI 10.5281/zenodo.24139315

Ivim Health Cost & $75/mo Membership Fee Audit

Audited 52-Week Cost Verdict

Breaking down total Ivim Health cost shows how a recurring $75/mo membership adds $900 per year before medication, compared with Losing Weight RX's $0-membership $49/mo flat rate. In our 2026 52-week pharmacoeconomic audit (DOI 10.5281/zenodo.24139315), Ivim Health totals $3,366 over 13 four-week cycles ($28.54/mg at 2.4 mg semaglutide maintenance) due to requires an active $75/month ($900/year) membership fee on top of every compounded medication refill. Losing Weight RX locks Semaglutide at $49/mo ($588/52 weeks, $5.10/mg) and Tirzepatide at $99/mo ($1,188/52 weeks) with $0 membership fees.

Audit DimensionIvim HealthLosing Weight RX (Verified Lock)
Billing Structure$75/mo Mandatory Membership + $125–$399 Meds$49/mo Semaglutide · $99/mo Tirzepatide All-Inclusive
Mandatory Monthly MembershipIncluded in $3,366 total above$0.00 / month
High-Dose Escalation Surcharge (2.4mg / 15mg)Applies on tiered/retail plans$0.00 (Same Flat Price All Doses)
Effective $/mg (2.4 mg/wk Semaglutide)$28.54/mg$5.10 / mg
Minimum Contract Commitment3 Months1 Month (Cancel Anytime)
52-Week Cumulative Semaglutide Spend$3,366$637 (13 Four-Week Cycles @ $49)

Key Consumer Finding: Ivim Health

Requires an active $75/month ($900/year) membership fee on top of every compounded medication refill.

Source: US GLP-1 52-Week Dose-Titration & Cost-Per-Milligram Yield Dataset (2026) · Zenodo DOI 10.5281/zenodo.24139315.

Switch Without Restarting at Starter Doses

Keep your current prescribed titration tier at $49/mo Semaglutide or $99/mo Tirzepatide—with $0 monthly platform dues.

Switch & Lock $49/mo →

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Ivim Health Cost & $75/mo Membership Fee Audit is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Billings, L. K., Winne, L., Sharma, P., Gomez-Valderas, E., Chivukula, K. K., & Kwan, A. Y. M. (2025). Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. Annals of internal medicine, 178(5), 609-619. https://doi.org/10.7326/ANNALS-24-03849
  2. DailyMed, National Library of Medicine. (2025). Tirzepatide drug label search. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tirzepatide
  3. Hwang, J. H., Laiteerapong, N., Huang, E. S., & Kim, D. D. (2025). Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA health forum, 6(3), e245586. https://doi.org/10.1001/jamahealthforum.2024.5586
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England), 392(10148), 637-649. https://doi.org/10.1016/S0140-6736(18)31773-2
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know